Engineered Probiotics Boost Immune Attack on Pancreatic Cancer

Salcedo's Battle Against Stage III Pancreatic Cancer

For 67-year-old grandfather Miguel Salcedo, the diagnosis came as a devastating blow after months of unexplained pain and swelling.

What began as routine visits to his doctor escalated into a series of medical tests when an endoscopic ultrasound failed to identify the cause of his discomfort, leading to a referral to a gastroenterologist who ordered an MRI scan.

Two days after that scan, Salcedo received the news that would change his life: Stage III pancreatic cancer.

"It was very hard to hear that diagnosis," Salcedo told reporters.

Like many patients with advanced pancreatic cancer, Salcedo was initially told that surgery—the most effective treatment for removing cancerous tumours—was not an option for him due to the location and spread of his disease.

• Stage III pancreatic cancer means the tumour has grown into nearby major blood vessels or lymph nodes but has not spread to distant organs
• Approximately 40% of pancreatic cancer patients are diagnosed at Stage III or IV
• Without treatment, Stage III patients typically survive just 3-6 months

Most Stage III pancreatic cancer patients survive only months after diagnosis, facing a five-year survival rate of just 15%, according to American Cancer Society statistics.

Salcedo's doctors offered him conventional chemotherapy, but explained that the benefits would likely be limited and temporary.

It was at this critical juncture that his medical team mentioned an experimental clinical trial testing the new engineered probiotic bacteria treatment.

Despite uncertainties about the experimental approach, Salcedo decided to enrol in the trial, a decision that would ultimately save his life.

Within weeks of beginning the probiotic treatment combined with a reduced chemotherapy regimen, Salcedo began to notice improvements.

The constant abdominal pain that had plagued him for months began to subside, and follow-up scans revealed that his tumours were shrinking—a response far better than his doctors had anticipated.

"I was able to play with my grandchildren again, something I thought I might never do," Salcedo said.

"The treatment gave me my life back when I thought I had lost it forever."

Now, more than two years since his diagnosis, Salcedo shows no evidence of active disease, a result his oncologist describes as nothing short of remarkable given the typically poor prognosis for his condition.

How Engineered Probiotics Work Against Cancer

The science behind this breakthrough hinges on the relationship between our microbiome and immune system, a connection researchers have been exploring for decades but only recently learned to manipulate effectively.

Probiotics are beneficial bacteria that naturally occur in fermented foods like yoghurt and are also available as supplements, traditionally used to support digestive health and restore balance to gut flora after antibiotic treatment.

In this innovative cancer therapy, scientists have genetically modified specific strains of these beneficial bacteria to produce proteins that stimulate immune cells called T-cells, which are the body's primary defence against cancer.

• The human gut contains approximately 100 trillion microorganisms, collectively weighing about 2kg
• Specific strains of lactobacillus and bifidobacterium are commonly used in probiotic therapies
• The engineered bacteria can survive the acidic environment of the stomach to reach the intestines

Once administered, these engineered bacteria travel through the digestive system and colonise the tissue surrounding the pancreas, where they begin releasing immune-stimulating compounds specifically in the tumour microenvironment.

This targeted approach is crucial because pancreatic tumours typically create a protective shield that prevents immune cells from penetrating and attacking the cancer—part of what makes this disease so difficult to treat.

The probiotic bacteria effectively break down this shield by releasing enzymes that degrade the tumour's protective barrier while simultaneously signalling immune cells to attack.

"Pancreatic tumours are like fortresses with thick walls," explained Dr James Chen, a microbiologist involved in the research.

"Our engineered bacteria act like Trojan horses, slipping past the defences and then calling in the cavalry—the patient's own immune system."

The treatment is typically administered orally in capsule form, making it significantly less invasive than many cancer therapies that require intravenous infusion or surgical implantation.

Patients in clinical trials reported fewer side effects compared to traditional chemotherapy, with most experiencing only mild digestive discomfort initially as their bodies adjusted to the probiotic treatment.

The bacteria used in the therapy are carefully selected strains with established safety records in humans, minimising the risk of infection or other adverse effects.

Researchers have also engineered the bacteria with a self-destruct mechanism that activates after approximately two weeks, ensuring they don't permanently colonise the body or cause unintended effects once their therapeutic work is complete.

Clinical Trial Results Surpass Expectations

Results from phase II clinical trials involving 237 patients with advanced pancreatic cancer have exceeded researchers' expectations, with the probiotic treatment group showing significantly improved outcomes compared to those receiving standard care alone.

Patients receiving the engineered probiotic therapy experienced an average progression-free survival of 8.4 months compared to 4.2 months for the control group, representing a doubling of the time before cancer continued to grow.

More impressively, overall survival for the probiotic group averaged 14.7 months versus 8.9 months for those receiving standard treatment—a difference that oncologists describe as clinically meaningful and potentially practice-changing.

• 23% of patients in the probiotic group showed partial tumour shrinkage compared to 9% in the control group
• 7% of probiotic patients achieved complete remission versus 2% in the standard treatment group
• Quality of life scores were 40% higher in the probiotic group according to standardised assessments

The trials also revealed that the probiotic treatment appears to enhance the effectiveness of chemotherapy when used in combination, allowing for lower doses of chemotherapy drugs while maintaining or improving anti-cancer effects.

This combination approach is particularly significant because chemotherapy side effects are often what limit treatment duration and effectiveness in pancreatic cancer patients, many of whom are already frail due to their disease.

"We've known for years that the microbiome influences cancer treatment outcomes, but this is the first time we've successfully engineered that relationship to our advantage," said Dr Rebecca Foster, an oncologist who led several of the clinical trial sites.

The trials included patients with both locally advanced and metastatic pancreatic cancer, with benefits observed across disease stages, though the effects were most pronounced in patients with earlier-stage disease.

Researchers noted that the treatment appeared most effective in patients with specific microbiome profiles, suggesting that personalised approaches based on individual bacterial composition might optimise results in future applications.

Importantly, the engineered probiotic bacteria did not show signs of developing resistance over time—a common problem with many cancer therapies that eventually stop working as tumours evolve.

The safety profile was also favourable, with only 12% of patients experiencing serious adverse events related to the probiotic treatment compared to 34% in the chemotherapy-only group.

Based on these promising results, regulatory agencies in both the UK and United States have granted fast-track designation for the treatment, potentially accelerating its path to approval for widespread clinical use.

The Desperate Need for New Pancreatic Cancer Treatments

Pancreatic cancer has long been termed the 'silent killer' because it typically causes no symptoms in its early stages, meaning most cases are diagnosed only after the disease has spread beyond the pancreas and become difficult to treat.

The pancreas sits deep within the abdomen, tucked behind the stomach and surrounded by other organs, making tumours difficult to detect during routine physical examinations and even challenging to see on standard imaging scans.

• Pancreatic cancer is the 5th most common cause of cancer death in the UK
• Less than 10% of patients are diagnosed early enough for potentially curative surgery
• Survival rates have barely improved over the past 50 years, unlike most other cancers

Current treatment options remain limited, with surgery offering the only potential cure but being possible in only about 10-20% of patients whose tumours are detected before spreading.

For the majority of patients, treatment focuses on controlling symptoms and extending life rather than achieving cure, typically involving chemotherapy combinations that have shown only modest benefits over the decades.

The standard chemotherapy regimen for pancreatic cancer, known as FOLFIRINOX, can extend survival by several months but often comes with debilitating side effects that significantly impact quality of life.

"We've been stuck in a treatment plateau for pancreatic cancer for far too long," said Professor David Williams, a leading oncologist at Guy's Cancer Centre in London.

"This probiotic approach represents the first genuinely new mechanism of action we've seen in years."

The desperate need for better treatments is reflected in the funding landscape, with pancreatic cancer receiving significantly less research funding per death than more common cancers like breast or prostate cancer.

Patients and their families have increasingly advocated for more research attention, leading to modest increases in funding but still leaving pancreatic cancer as one of the most underfunded areas of oncology relative to its mortality burden.

The biological challenges of pancreatic cancer are formidable—the tumours develop a dense fibrotic tissue that creates a physical barrier to drug delivery, and the cancer cells themselves develop sophisticated mechanisms to evade immune detection.

This microenvironment also creates high internal pressure within tumours, effectively collapsing blood vessels and preventing chemotherapy drugs from reaching cancer cells in effective concentrations.

The engineered probiotic approach bypasses many of these barriers by using the digestive tract as a delivery route and activating the immune system from within the tumour itself rather than relying on systemic circulation.

This biological advantage may explain why the treatment has shown promise where so many others have failed, offering hope that the decades-long stagnation in pancreatic cancer outcomes may finally be ending.

What This Means for Patients and the Future of Cancer Treatment

For patients currently facing pancreatic cancer, the engineered probiotic treatment offers hope where there has been precious little, though experts caution that it will likely be several more years before the therapy becomes widely available outside of clinical trials.

The research team has already begun planning phase III trials—the final stage before regulatory approval—which will involve thousands of patients at multiple medical centres across the UK, Europe, and North America.

These larger studies will aim to confirm the benefits seen in earlier trials and identify which patients are most likely to respond to the treatment, helping doctors personalise therapy recommendations.

• If approved, the treatment could be available as early as 2028 for eligible pancreatic cancer patients
• Researchers are exploring similar probiotic approaches for other difficult-to-treat cancers including ovarian and glioblastoma
• The treatment is expected to cost approximately £15,000 per course, comparable to many targeted cancer therapies

Beyond pancreatic cancer, scientists are already investigating whether similar engineered probiotic approaches could be effective against other solid tumours that have proven resistant to conventional treatments.

Early research suggests the technology might be particularly valuable for cancers that form in or near the digestive tract, where probiotic bacteria can naturally colonise, including colorectal, stomach, and liver cancers.

The success of this approach also validates the broader concept of microbiome-based medicine, which seeks to harness the trillions of microorganisms living in and on our bodies for therapeutic benefit.

"This is just the beginning," said Dr Mitchell.

"We're looking at a whole new class of cancer treatments that work with the body rather than against it."

For patients like Miguel Salcedo, who has now been cancer-free for more than two years, the treatment represents more than just scientific progress—it represents the gift of time with family that seemed impossible when he first received his diagnosis.

"I've watched my granddaughter start school and celebrated another wedding anniversary," Salcedo said.

"These are moments I thought I wouldn't have, and I have this treatment to thank for them."

As research continues and more clinical trials open, oncologists are cautiously optimistic that this breakthrough could mark a turning point in the battle against one of medicine's most formidable opponents.

The journey from laboratory discovery to standard treatment is long and filled with regulatory hurdles, but for patients facing pancreatic cancer today, the existence of promising new options offers something equally valuable: hope.

"We've moved from asking whether we can treat pancreatic cancer to asking how we can treat it better," said Professor Williams.

"That shift in perspective represents the most important advance of all."